Search Result

Results for "

Azido-mono-amide-DOTA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) Biochemical Assay Reagents (3) CXCR (4) FAP (1) Fluorescent Dye (1) GCGR (2) Neuropeptide Y Receptor (2) Radionuclide-Drug Conjugates (RDCs) (7) Somatostatin Receptor (1)
By Research Areas:	Cancer (6) Infection (1) Metabolic Disease (3) Neurological Disease (3)
Click Chemistry:	Azide (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Click Chemistry

Targets Recommended: FAAH Acyltransferase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-W539916

**Azido-mono-amide-DOTA**	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-158065

Azido-mono-amide-DOTA-tris(t-Bu ester)	Biochemical Assay Reagents	Others
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer .

HY-P10444

DOTA Conjugated JM#21 derivative 7	CXCR Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney .

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is utilized for diagnosis and therapy of cancer, through combination with radioactive elements .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging .

Cat. No.	Product Name	Type

HY-W539916

**Azido-mono-amide-DOTA**	Chelators
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-158065

Azido-mono-amide-DOTA-tris(t-Bu ester)	Chelators
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .

Cat. No.	Product Name	Target	Research Area

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P5025

*Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle)* Azido-c(RGDyK)	Peptides	Others
Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle) (Azido-c(RGDyK)) is a polypeptide composed of arginine, glycine, aspartic acid, and tyrosine that can be used for Synthesis of [ ¹⁸F]FPyKYNE-c(RGDyK) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10131

3BP-3940	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10026

Nisotirostide LY-3457263	Peptides	Metabolic Disease
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Peptides	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer .

HY-P10444

DOTA Conjugated JM#21 derivative 7	CXCR Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney .

HY-P10273

DOTA-Octreotide	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is utilized for diagnosis and therapy of cancer, through combination with radioactive elements .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging .

Cat. No.	Product Name		Classification

HY-W539916

**Azido-mono-amide-DOTA**		Azide
Azido-mono-amide-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. Azido-mono-amide-DOTA can be used for conjugation of peptides and radionuclides.

HY-158065

Azido-mono-amide-DOTA-tris(t-Bu ester)		Azide
Azido-mono-amide-DOTA-tris(t-Bu ester) is a biochemical assay reagent, and is a click chemistry reagent .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: